If you have a spare $4000 laying around, you can get the full copy of this business intelligence report. If not, we have to be content with this press release. I’m assuming that a variety of pharma companies are buying it. I also don’t think some of the statements (in this summary, at least) take into account the probability of intrathecal administration of Elaprase coming online.
The new report* found that Elaprase (idursulfase) has had a positive effect in increasing the treated patient pool since its launch as the first and only approved product used to treat Hunter syndrome in Europe in 2006 and Japan in 2007. Until the launch of Elaprase, the treatment options for Hunter syndrome were palliative rather than successful in treating underlying lysosomal enzyme deficiencies.
However, despite the breakthrough of Elaprase, GlobalData estimates that the global Hunter syndrome therapeutics market still has an unmet need of 57%. This is due to limited treatment options with novel mechanisms of action, the high cost of therapy, and the low to moderate safety and efficacy profile of Enzyme Replacement Therapy (ERT), which is the only approved treatment.
The complex etiology and pathophysiology of the disease makes the clinical development of new therapies challenging, which may be acting as a deterrent and discouraging pharmaceutical companies from initiating research programs in this area. Indeed, there are only two molecules in the clinical phase of development and both of these molecules are product extensions of the already approved ERT. Moreover, the pipeline has no molecules with novel mechanisms of action or with better safety and efficacy profiles.
A weak pipeline with no novel, first-in class molecules opens up opportunities for healthcare companies to gain market share in the future. GlobalData expects the value of the global Hunter syndrome therapeutics market to grow from US$292.1 million in 2011 to an estimated US$374.6 million by 2019 as awareness of the disease increases.
Elaprase is expected to continue as the gold-standard therapy for the treatment of Hunter syndrome after diagnosis. However, the market offers significant opportunities for newer, cost-effective treatment options with novel mechanisms of action or with better safety and efficacy profiles, to the benefit of both pharmaceuticals companies and patients.
NOTES TO EDITORS
Hunter Syndrome Therapeutics – Pipeline Assessment and Market Forecasts to 2019
The report is an essential source of information and analysis on the global Hunter syndrome market, providing insights into the key trends shaping the development of therapeutics, the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, it provides valuable insights into the pipeline products within sector. This report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.
ABOUT GLOBALDATA
GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries
